post-operative spinal fusion infection. Other and unspecified infectious diseases
Conditions
Interventions
Intervention group: Using Apixaban for DVT/PE prevention.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: All patients aged 18 to 75 who are candidates for elective spinal fusion surgery. Patients who meet the inclusion criteria and have no contraindications to anticoagulant medications.
Exclusion criteria
Exclusion criteria: Bleeding or active coagulation disorders: Patients with bleeding problems such as hemophilia, vitamin K deficiency, or genetic disorders leading to uncontrollable bleeding must be excluded from the study. Active infection at the surgical site: Patients who have an active infection in the spine or other parts of the body at the time of surgery or beforehand will be excluded due to the high risk of wound infections and other complications. Known allergy or hypersensitivity to study medications: Patients with hypersensitivity to anticoagulant medications used in the study (such as Apixaban or ASA) must be excluded. Pregnancy or breastfeeding: Due to physiological and hormonal changes that may affect treatment, as well as potential risks for the fetus or infant, patients who are pregnant or breastfeeding will be excluded from the study. Chronic or advanced diseases: Patients with uncontrolled chronic diseases (such as advanced renal or hepatic failure) or conditions that impair wound healing must be excluded. Emergency surgeries or procedures requiring urgent intervention: Patients undergoing emergency surgeries will not be included in the study due to significant differences in treatment protocols and the need for immediate interventions. Inability to provide informed consent: Patients who, for any reason, are unable to understand the study details or provide informed consent will be excluded. History of previous spinal surgeries. History of surgical site infection following non-spinal surgeries. History of hypercoagulability, DVT, or PTE.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surgical site infection. Timepoint: 2 weeks; 1 month; 3 months after surgery. Method of measurement: clinical evaluation and inflammatory markers evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Chehrassan
Iran University of Medical Sciences
Outcome results
None listed